Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0VJROY
ADC Name
SGN-B6A
Synonyms
SGN-B6A; SGNB6A; humanized IgG1 beta-6 monoclonal antibody conjugated to monomethyl auristatin E
   Click to Show/Hide
Organization
Seagen Inc.
Drug Status
Phase 1
Indication
In total 11 Indication(s)
Bladder cancer [ICD11:2C94]
Phase 1
Esophageal cancer [ICD11:2B70]
Phase 1
Esophageal squamous cell carcinoma [ICD11:2B71]
Phase 1
Gastric cancer [ICD11:2B72]
Phase 1
Gastroesophageal junction cancer [ICD11:2B71]
Phase 1
Head and neck squamous carcinoma [ICD11:2C31]
Phase 1
HER2(-) breast cancer [ICD11:2C60-2C65]
Phase 1
Non-small cell lung cancer [ICD11:2C25]
Phase 1
Ovarian cancer [ICD11:2C73]
Phase 1
Pancreatic cancer [ICD11:2C10]
Phase 1
Skin squamous cell carcinoma [ICD11:2C31]
Phase 1
Drug-to-Antibody Ratio
4
Structure
Antibody Name
Human ITGB6 SGN-B6A mAb
  Antibody Info 
Antigen Name
Integrin beta-6 (ITGB6)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
Vedotin
DrugMap ID
DMATJL9
TTD ID
DJYD13
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT04389632
Phase 1/2
A phase 1 study of SGN-B6A in advanced solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Patients with metastatic or unresectable solid tumors.
Administration Dosage
30 patients in Q1W (0.80, 1.00, and 1.20 mg/kg); 18 patients in 2Q3W (1.20 or 1.25 mg/kg).
Related Clinical Trial
NCT Number NCT04389632  Clinical Status Phase 1/2
Clinical Description A phase 1 study of SGN-B6A in advanced solid tumors.
References
Ref 1 Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors. J Clin Oncol. 2021 39:15_suppl, 2631-2631.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.